Clinical Trials | October 25, 2025
Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
These findings follow positive Phase 3 results presented earlier this year
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Subscribe To Our Newsletter & Stay Updated
